ClinicalTrials.gg
RecruitingNCT07334561Updated Sep 4, 2026

Transcranial Electrical Stimulation for Comorbid Depression and Chronic Pain

An interventional study of tDCS and alpha-tACS in Depression Disorder and Chronic Pain, sponsored by Shanghai Mental Health Center. Recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Shanghai Mental Health Center · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Chronic Pain with a site in China — 14 open to participants now, 15 under way, 1 of them phase 3. Chronic Pain · China.

Planned enrollment
10th of 34
160 · median 80
Started
2026
with 3 others
No phase
21 of 43
8 open now
Primary completion
2028-02
later than 12 of 14 live
Registered
40th of 43
by date

Among the 43 studies in Chronic Pain with a site in China, this one is the 10th largest by planned enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2026, is one of 21 with no phase, reaches primary completion later than 12 of the 14 other live ones, and was the 40th registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

14 of the 43 studies in Chronic Pain with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Chronic Pain with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if active transcranial alternating current stimulation (tACS) and transcranial direct current stimulation (tDCS) can improve pain symptoms in patients with major depressive disorder (MDD) and chronic pain symptoms. It will also explore the neural mechanisms underlying these potential effects. The main questions it aims to answer are:

  1. Are there any differences in the overall efficacy among the three intervention groups (tACS, tDCS, and sham)?
  2. Is active tACS superior to sham stimulation in reducing pain symptoms in patients with MDD and chronic pain over the 2-week treatment period and at the 6-week follow-up?
  3. Is active tACS superior to active tDCS in reducing pain symptoms?
  4. Does active tACS, compared to tDCS, demonstrate a more persistent improvement in pain symptoms, as measured at the 6-week follow-up?
  5. As an exploratory objective, what neural oscillation entrainment mechanisms underlie the potential analgesic effects of tACS?

Researchers will compare three parallel groups: active tACS, active tDCS, and sham stimulation, to evaluate their efficacy. All three groups are randomized and double-blinded.

In addition, a separate exploratory open-label cohort of 10 participants will receive the same active tACS intervention while performing a cognitive task. This exploratory arm is designed to investigate the neural oscillation entrainment effects of tACS. Data from this arm will be analyzed separately and are not included in the primary confirmatory analyses.

Participants in the main randomized trial will:

  1. Receive 40 minutes of stimulation (tACS, tDCS, or sham) once daily, 5 days per week, for 2 weeks (10 sessions total).
  2. Complete clinical assessments and cognitive tests at baseline, mid-intervention (week 1), post-intervention (week 2), and at a 6-week follow-up.
  3. Undergo resting-state functional MRI (rs-fMRI) and blood sample collection at baseline and post-intervention for exploratory biomarker analyses.

Participants in the exploratory open-label arm will:

  1. Receive active tACS (1 mA, 10 Hz, 40 minutes) once daily, 5 days per week, for 2 weeks (10 sessions total), while performing a cognitive task during stimulation.
  2. Complete resting-state and task-state EEG recordings at the following time points:

(1) At baseline (pre-intervention) (2) Immediately before and after the 1st tACS session (3) Immediately before and after the 10th tACS session (4) On the day after completion of all 10 sessions These EEG recordings are designed to assess: (1) the immediate entrainment effects of a single tACS session, (2) the cumulative effects after repeated tACS sessions, and (3) the persistent neural plasticity changes following the full intervention course.

03

Conditions studied

  • Depression Disorder
  • Chronic Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meets the diagnostic criteria for a depressive episode ();
  2. HAMD-17 score of ≥8 and ≤23 (mild-to-moderate depressive symptoms) based on the current assessment;
  3. 4 or higher on Item 5 of the Brief Pain Inventory (BPI), and persistent pain lasting more than three months;
  4. Ages 18-80;
  5. Right-handed, with normal hearing, vision, or corrected vision;
  6. Have a high school education or higher and be able to understand and complete research-related assessments;
  7. Maintain a consistent regimen of analgesic and antidepressant medications and psychotherapy (including dosage and type of medication or treatment method) for four weeks prior to enrollment;
  8. The subject (or his or her legal representative, if applicable) signed an form stating that he or she understood the purpose and procedure of the trial and was willing to participate in it.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed according to the as meeting any of the following criteria: ① Major depressive disorder or treatment-resistant depression (HAMD-17 score ≥ 24, and the current episode has lasted ≥ 2 years, or the current episode has been unresponsive to treatment with ≥ 2 antidepressants); ② Schizophrenia spectrum disorder; ③ Bipolar I disorder; ④ Anxiety disorders (including generalized anxiety disorder, panic disorder, social anxiety disorder, etc.); ⑤ Depressive disorder caused by a medical condition.
  2. Experiencing malignant pain caused by cancer pain syndrome, visceral pain (such as stomach pain), referred pain (such as back pain caused by pancreatitis), and so on;
  3. Patients with severe or unstable physical illnesses, including but not limited to: neurological disorders (such as epilepsy, stroke, migraine, history of cranial surgery, etc.); neurological disorders accompanied by structural brain abnormalities (e.g., traumatic brain injury, recent stroke, brain tumor); cardiovascular diseases (e.g., uncontrolled hypertension, heart failure, arrhythmias, myocardial infarction, etc.); respiratory diseases (e.g., severe sleep apnea syndrome); malignant tumors or immunodeficiency; uncontrolled diabetes (fasting blood glucose > 12 mmol/L);
  4. Excessive alcohol consumption within 30 days prior to the start of the trial, or a history of alcohol or drug dependence within the past 6 months;
  5. Women who are pregnant, breastfeeding, or planning to become pregnant within 3 months of the start of the trial;
  6. Currently taking medications that affect cortical excitability (e.g., benzodiazepines, antiepileptic drugs);
  7. Have undergone neurostimulation therapy within the past 3 months, including electroconvulsive therapy (MECT), repetitive transcranial magnetic stimulation (rTMS), or transcranial electrical stimulation (tES);
  8. Suffers from claustrophobia and is unable to undergo an fMRI scan (applies to subjects who require a functional MRI scan);
  9. to transcranial electrical stimulation (such as intracranial metal implants, pacemakers, cochlear implants, skin abrasions at the stimulation site, or a personal or family history of epilepsy, etc.);
  10. Currently participating in another clinical trial, has participated in a clinical trial within the past 90 days, or plans to participate in another clinical trial during the study;
  11. Participants with obvious suicidal tendencies, impulsive behavior, or an inability to cooperate with study evaluators;
  12. Accompanied by psychotic symptoms;
  13. Researchers believe there are other circumstances that make a participant unsuitable for the trial;
  14. Patients with severe cognitive impairment ( ≤ 17) were excluded;
  15. Participants who are unable to cooperate with the study;
  16. Those who voluntarily withdrew midway.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    tDCS

    Participants receive active tDCS. The anodal electrode is placed over the left dorsolateral prefrontal cortex (F3), and the cathodal electrode is placed over the right dorsolateral prefrontal cortex (F4). A constant current of 2 mA is applied for 40 minutes per session, with a 30-second ramp-up and ramp-down period. The intervention is administered once daily for 2 weeks (total of 10 sessions).

    Device: tDCS

  • Experimental
    alpha-tACS

    Participants receive active alpha-tACS. Two electrodes are placed over F3 and F4. A sinusoidal alternating current at 10 Hz frequency (alpha band) is applied 1 mA (zero-to-peak) at the F3 and F4 electrodes. Stimulation duration is 40 minutes per session, including 30-second ramp-up and ramp-down periods. The intervention is administered once daily, 5 days per week, for 2 weeks (total of 10 sessions).

    Device: alpha-tACS

  • Sham comparator
    Sham

    Sham group using the same electrode montage at F3/F4. To maintain blinding, the stimulator delivers current only during the initial 30-second ramp-up period, followed by an immediate ramp-down, and a final 30-second ramp-up at the end of the stimulation session. This mimics the initial sensation of active stimulation without delivering sufficient current to induce neural modulation.

    Device: Sham

  • Experimental
    Exploratory Open-Label tACS Group

    Participants in this exploratory arm receive the same active tACS intervention as Arm alpha-tACS, with identical stimulation parameters (e.g., 1 mA, 40 minutes, 10 Hz, targeting the bilateral dorsolateral prefrontal cortex (DLPFC)). This arm is open-label (unblinded): participants and study personnel are aware of the treatment assignment. It serves as a supplementary exploratory cohort to explore preliminary neural oscillation entrainment effects of tACS. Unlike Arms 1-3, this arm is neither randomized nor blinded. Data from this arm will be analyzed separately and are not included in the primary confirmatory hypothesis testing of the randomized controlled trial. The overall study remains double-blind for the three-arm RCT component, with this exploratory arm conducted as an ancillary cohort.

    Device: alpha-tACS

Interventions

  • DevicetDCS

    Participants receive active tDCS. The anodal electrode (5 × 5 cm) is placed over the left dorsolateral prefrontal cortex (F3), and the cathodal electrode (5 × 7 cm) is placed over the right dorsolateral prefrontal cortex (F4). A constant current of 2 mA is applied for 40 minutes per session, with a 30-second ramp-up and ramp-down period. The intervention is administered once daily for 2 weeks (total of 10 sessions).

  • Devicealpha-tACS

    Participants receive active alpha-tACS. Two electrodes are placed over F3 and F4. A sinusoidal alternating current at 10 Hz frequency (alpha band) is applied 1 mA (zero-to-peak) at the F3 and F4 electrodes. Stimulation duration is 40 minutes per session, including 30-second ramp-up and ramp-down periods. The intervention is administered once daily, 5 days per week, for 2 weeks (total of 10 sessions).

  • DeviceSham

    Sham group using the same electrode montage at F3/F4. To maintain blinding, the stimulator delivers current only during the initial 30-second ramp-up period, followed by an immediate ramp-down, and a final 30-second ramp-up at the end of the stimulation session. This mimics the initial sensation of active stimulation without delivering sufficient current to induce neural modulation.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving MCID on BPI Pain Intensity Subscale

    Description: The BPI is a validated self-administered questionnaire that assesses the severity of pain and its impact on daily functioning. The pain intensity subscale consists of four items rating pain at its "worst," "least," "average," and "current" (right now). Each item is rated on a 0 to 10 numeric rating scale. Higher scores mean a worse outcome. The Minimal Clinically Important Difference (MCID) is defined as a reduction of ≥ 1 point from baseline in the BPI pain intensity score. The outcome is the proportion of participants in each group who achieve this MCID threshold at each follow-up time point.

    Time frame: At 1 week (mid-intervention), 2 weeks (end of intervention), and 6 weeks (follow-up) post-baseline

Secondary outcomes

  1. Percentage Reduction from Baseline in HAMD-17 Total Score

    The HAMD-17 is a 17-item clinician-rated scale assessing depression severity. Items are rated on 3- or 5-point scales, with total scores ranging from 0 to 52. Higher scores mean a worse outcome (greater depression severity). The outcome is the percentage reduction in HAMD-17 total score from baseline at each follow-up time point, calculated using the formula: \[(Baseline score - Follow-up score) / Baseline score\] × 100% A positive percentage indicates improvement (reduction in depressive symptoms).

    Time frame: At 1 week (mid-intervention), 2 weeks (end of intervention), and 6 weeks (follow-up) post-baseline

  2. Change from Baseline in HAMD-17 Total Score

    The Hamilton Depression Rating Scale (HAMD-17) is a 17-item clinician-rated scale assessing depression severity. Items are rated on 3- or 5-point scales, with total scores ranging from 0 to 52. Higher scores indicate greater depression severity (worse outcome). The outcome is the absolute change in the total score from baseline at each follow-up time point, calculated as: \[(Baseline score) - (Follow-up score)\]. A positive change value indicates improvement (reduction in depressive symptoms). No pre-defined clinically meaningful threshold is applied to this continuous outcome; it is reported as the mean absolute change per group.

    Time frame: At 1 week (mid-intervention), 2 weeks (post-intervention), and 6 weeks (follow-up)

  3. Change from Baseline in Pain Catastrophizing Scale (PCS) Total Score

    The Pain Catastrophizing Scale (PCS) is a 13-item self-reported questionnaire. Each item is rated on a 5-point Likert scale from 0 (not at all) to 4 (all the time), with total scores ranging from 0 to 52. Higher scores indicate higher levels of pain catastrophizing (worse outcome). The outcome is the absolute change in the total score from baseline at each follow-up time point, calculated as: \[(Baseline score) - (Follow-up score)\]. A positive change value indicates improvement (reduction in pain catastrophizing).

    Time frame: At 1 week (mid-intervention), 2 weeks (end of intervention), and 6 weeks (follow-up) post-baseline

  4. Change from Baseline in Generalized Anxiety Disorder Scale-7 (GAD-7) Total Score

    The GAD-7 is a 7-item self-report scale (0-21, higher scores = worse outcome) assessing anxiety symptoms over the past two weeks. The outcome is the absolute change in the total score from baseline at each follow-up time point, calculated as: \[(Baseline score) - (Follow-up score)\].

    Time frame: At 1 week (mid-intervention), 2 weeks (end of intervention), and 6 weeks (follow-up) post-baseline

  5. Change from Baseline in Clinical Global Impression (CGI) Total Score

    The Clinical Global Impression (CGI) scale consists of two clinician-rated subscales assessing overall treatment response: CGI-Severity (CGI-S): Rates the severity of the patient's illness on a 7-point scale from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Higher scores mean a worse outcome. CGI-Improvement (CGI-I): Rates the patient's improvement compared to baseline on a 7-point scale from 1 (very much improved) to 7 (very much worse). This subscale is only assessed at post-baseline time points. Lower scores mean a better outcome (greater improvement). The outcome is the change from baseline in CGI-S score at each follow-up time point, and the CGI-I score at each post-baseline time point.

    Time frame: At 1 week (mid-intervention), 2 weeks (post-intervention), and 6 weeks (follow-up)

  6. Change from Baseline in Resting-State Functional Connectivity of the DLPFC at 2 Weeks

    Resting-state functional connectivity (rs-FC) of the dorsolateral prefrontal cortex (DLPFC) is assessed using resting-state functional magnetic resonance imaging (rs-fMRI). The primary measurement is the change in seed-based functional connectivity strength between the DLPFC and its target network regions (e.g., parietal cortex, default mode network nodes), quantified as Fisher-transformed correlation coefficients (z-values) from a priori defined regions of interest. Higher z-values indicate stronger positive functional connectivity; lower or negative values indicate weaker or anticorrelated connectivity. Structural MRI (sMRI) is acquired for co-registration and normalization purposes.

    Time frame: Baseline and immediately after the 2-week intervention period

Other outcomes

  1. Change from Baseline in Brain-Derived Exosome Metabolite Levels

    Metabolite profiles are measured using untargeted liquid chromatography-mass spectrometry (LC-MS) in plasma-derived brain-enriched exosomes. Changes in metabolite profiles from baseline to post-intervention are assessed using multivariate partial least squares discriminant analysis (PLS-DA). The primary comparison is the separation distance (e.g., Q² or R² values) between baseline and post-intervention clusters, with positive values indicating greater separation between the two time points. This is an exploratory outcome to identify potential metabolic biomarkers and generate hypotheses related to the mechanisms of tACS/tDCS action. Results will be reported descriptively and are not part of the primary confirmatory analysis.

    Time frame: From baseline to post-intervention at 2 weeks

  2. Change from Baseline in BPI Pain Intensity Score in the Exploratory Open-Label Cohort

    This exploratory outcome measures the change from baseline in the BPI Pain Intensity score after 10 sessions of active tACS in the open-label arm. Data are reported descriptively as individual change values, mean change, standard deviation, and within-group effect size (Cohen's d) . No formal hypothesis testing is planned; the results will inform effect size estimation for future trial planning.

    Time frame: From baseline to post-intervention at 2 weeks

  3. Change from Baseline in HAMD-17 Total Score in the Exploratory Open-Label Cohort

    This exploratory outcome measures the change from baseline in HAMD-17 total score after 10 sessions of active tACS in the open-label arm. Data are reported descriptively as individual change values, mean change, standard deviation, and within-group effect size (Cohen's d). No formal hypothesis testing is planned; the results will inform effect size estimation for future trial planning.

    Time frame: From baseline to post-intervention at 2 weeks

  4. Change from Baseline in GAD-7 Total Score in the Exploratory Open-Label Cohort

    This exploratory outcome measures the change from baseline in GAD-7 total score after 10 sessions of active tACS in the open-label arm. Data are reported descriptively as individual change values, mean change, standard deviation, and within-group effect size (Cohen's d). No formal hypothesis testing is planned. GAD-7 scores will also be explored as a covariate in pain outcome analyses.

    Time frame: From baseline to post-intervention at 2 weeks

  5. Change from Baseline in Resting-State EEG Power Spectra in the Exploratory Open-Label Cohort

    Resting-state EEG is recorded for 5 minutes with eyes open and 5 minutes with eyes closed using a 64-channel EEG system. The primary measure is the change from baseline in spectral power (absolute and relative) across frequency bands (delta: 1-4 Hz, theta: 4-8 Hz, alpha: 8-12 Hz, beta: 12-30 Hz, gamma: 30-50 Hz), with a focus on the alpha band (8-12 Hz) due to the 10 Hz tACS intervention. Data are analyzed descriptively without formal hypothesis testing.

    Time frame: Baseline, Day 1 (immediately before and after the 1st tACS session), Day 10 (immediately before and after the 10th tACS session), and Day 11 (on the day after completion of all 10 sessions)

  6. Change from Baseline in Task-State EEG (Event-Related Potentials) in the Exploratory Open-Label Cohort

    Task-state EEG is recorded while participants perform a cognitive task (e.g., working memory or attention task). The primary measure is the change from baseline in event-related potential (ERP) components and task-related spectral power changes (event-related desynchronization/synchronization). Data are analyzed descriptively without formal hypothesis testing.

    Time frame: Baseline and Day 11 (on the day after completion of all 10 tACS sessions)

  7. Change from Baseline in Resting-State EEG Functional Connectivity in the Exploratory Open-Label Cohort

    Resting-state EEG functional connectivity is assessed using coherence and phase-locking value (PLV) between electrode pairs, with a focus on the alpha band and the DLPFC region. Data are analyzed descriptively without formal hypothesis testing.

    Time frame: Baseline and Day 11 (on the day after completion of all 10 sessions)

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2028, 15 months later.

Of 1,295 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 15 months is below that.

Counting every sponsor, half of 1,378 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2026
First posted
Jan 12, 2026
StartEst.
Nov 2026
Primary completionEst.
Feb 2028
CompletionEst.
Jun 2028
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07334561
Collaborators
Shanghai 10th People's Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Nov 2026 (estimated)
Primary completion
Feb 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Sep 4, 2026

Study contacts

Jianhua Chen
Contact
jianhua.chen@smhc.org.cn
(+86) 18017311011

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion